For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...
Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Panelists discusses how the ...
The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, ...
The American Thoracic Society (ATS) today announced a major quality improvement initiative aimed at tackling the persistent ...
Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 25 mg performed better than placebo when assessing rate of pulmonary exacerbations and lung ...
— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...
The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...
—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a ...
— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — NCFB is a chronic and progressive disease that can lead to permanent lung ...
Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results